A Microbiota‐ and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4
Advanced Science · 2026
DOI: 10.1002/advs.202512444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Junming He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China. Hauptthemen laut MEDLINE: Interleukin-15, Immunity, Innate, Microbiota, Precursor Cells, B-Lymphoid. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research & Developmental Program of China, Anhui provincial Department of Education.
Abstract (Originalsprache)
While natural killer (NK) cells and B cells arise from common lymphoid progenitors, the existence and nature of cells co‐expressing markers of both lineages (NK‐B cells) remain controversial. Here, this work identifies a significant population of CD3 − NKp46 − CD19⁺NK1.1⁺ cells, termed NK‐B cells, enriched in phosphoinositide‐dependent protein kinase‐1(PDK1)‐deficient mice but also present in wild‐type bone marrow. Single‐cell RNA sequencing and high‐dimensional flow cytometry reveal these NK‐B cells reside within early B cell developmental stages (pro‐B/pre‐B). Functionally, upon adoptive transfer into lymphocyte‐deficient hosts, NK‐B cells preferentially differentiated into B cells. Unlike conventional B cell precursors, NK‐B cells exhibit innate characteristics, including the capacity to secrete interferon‐gamma (IFN‐γ) and transforming growth factor‐beta (TGF‐β), and expressed CD122 (IL‐2/15Rβ) and Toll‐like receptor 9 (TLR9). Using a novel E4 promoter‐binding protein 4 (E4BP4) reporter model, this work demonstrates that both interleukin‐15 (IL‐15) signaling (via CD122) and TLR9‐mediated sensing of the gut microbiota cooperatively sustain E4BP4 expression within these progenitors. Consequently, germ‐free mice and mice deficient in IL‐15 or E4BP4 exhibit a profound loss of NK‐B cells. These findings unveil a distinct E4BP4‐expressing, innate‐like B cell progenitor pathway regulated by microbiota and IL‐15.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.
- Institute for Organ Transplant and Bionic Medicine, Tsinghua University, Beijing, 102218, China.
- State Key Laboratory of Membrane Biology, School of Medicine and Institute for Immunology, Tsinghua University, Beijing, 100084, China.
- Department of Allergy, the First Affiliated Hospital of Anhui Medical University and Institute of Clinical Immunology, Anhui Medical University, Hefei, 230032, China.
- Innovative Institute of Tumor Immunity and Medicine (ITIM), Hefei, 230032, China.
- Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, 230032, China.
ORCID-Profile: Junming He, Shasha Chen, Meixiang Yang, Zhongjun Dong
Förderung
- National Natural Science Foundation of China
- National Key Research & Developmental Program of China
- Anhui provincial Department of Education
Zitieren
APA
He, J., Hou, X., Feng, X., Dong, Y., Ren, M., Deng, S., Yang, X., Chen, D., Zhao, L., Chen, S., Yang, M., & Dong, Z. (2026). A Microbiota‐ and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4. Advanced Science. https://doi.org/10.1002/advs.202512444
Vancouver
He J, Hou X, Feng X, Dong Y, Ren M, Deng S, et al. A Microbiota‐ and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4. Advanced Science. 2026. doi:10.1002/advs.202512444
BibTeX
@article{He2026,
author = {He, Junming and Hou, Xinlei and Feng, Xiaomei and Dong, Yayun and Ren, Mengqi and Deng, Surong and Yang, Xinru and Chen, Donglin and Zhao, Lingna and Chen, Shasha and Yang, Meixiang and Dong, Zhongjun},
title = {A Microbiota‐ and IL‐15‐Dependent Innate‐Like B Cell Progenitor Expressing E4BP4},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202512444}
}
EUVIMED